Introduction Osteoporosis and fragility fracture are more frequently found in systemic lupus erythematosus (SLE) patients than in normal population. This study aims to determine the risk factors in ...
Objective To evaluate the safety and durability of telitacicept treatment in patients with SLE by identifying the reasons for treatment discontinuation and potential risk factors for subsequent ...
Objectives To define a clinically meaningful treatment response definition for haemolytic anaemia, that will form part of a novel multidomain outcome measure for SLE clinical trials.Methods An ...
Background Although the increased risk of cardiovascular disease in patients with SLE is well-documented, effective tools for risk stratification remain elusive. This study sought to explore the ...
Objective Biologics for systemic lupus erythematosus (SLE) demonstrate variable treatment responses across trials. We evaluated baseline biomarkers as predictors of response to guide personalised ...
Objectives Our current understanding of the genetic architecture of childhood-onset SLE (cSLE) is limited by a dearth of comprehensive genomic studies in cSLE. We have quantified the number of known ...
Objective Skeletal fragility is a major comorbidity in systemic lupus erythematosus (SLE), yet the accuracy of fracture risk algorithms in this population remains uncertain. We compared the ...
Objective Dyslipidaemia in systemic lupus erythematosus (SLE) contributes to pathogenesis and cardiovascular risk. The effect of statin therapy on SLE disease activity remains controversial. This meta ...
Background Current diagnosis of antiphospholipid syndrome (APS) relies on antiphospholipid antibodies (aPL) testing, but false-positive aPL results and asymptomatic aPL carriers pose significant ...
Objective To compare preconception disease-activity indices—systemic lupus erythematosus Disease Activity Score low disease activity (SLE-DAS LDA), lupus low disease activity state (LLDAS) and SLE-DAS ...
Background The long-term trajectories of estimated glomerular filtration rate (eGFR) and their relation to early proteinuria trajectories in biopsy-proven lupus nephritis (LN) are unclear. We aimed to ...
Case 1: A 35-year-old woman of Hispanic ancestry A 35-year-old woman of Hispanic ancestry received a diagnosis of systemic lupus erythematosus (SLE) in June 2021, based on polyarthralgia/itis, malar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results